The tumor-suppressive function of the unique H domain of FCGBP and its potential asa therapeutic target in colorectal cancer

Sep 22, 2026

Colorectal cancer remains a major cause of global morbidity and mortality, and current biomarkers and treatments are limited by late diagnosis and variable responses. This research investigates the role of the H domain of the Fc fragment of IgG binding protein (HFCGBP) as a candidate tumor suppressor in colorectal cancer and evaluates its clinical significance. Using clinical samples and functional assays, the study links FCGBP downregulation to worse tumor stage and grade, while HFCGBP overexpression suppresses proliferation and migration, and bioinformatics identifies involved signaling pathways, supporting its therapeutic and prognostic potential.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages16

Reading Time40 min

AccessFree to download

Background

Methods

Results

Keywords

Liu et al. BMC Cancer (2026) 26:450 BMC Cancer [https://doi.org/10.1186/s12885-026-15718-8](https://doi.org/10.1186/s12885-026-15718-8) RESEARCH Open Access The tumor-suppressive function of the unique H domain of FCGBP and its potential asa therapeutic target in colorectal cancer Qiao Liu1†, Hong-ying Jiao 1†, Yuan-yuan Wang1, Liao-liao Zhu2, Ni Wang1, Chong Liu3, Jing Tian1, Qian-nan Wang 1, Yang Li4, Wei Zhang1*, Na Ning1* and Li Gong1* Abstract Background Colorectal cancer (CRC) is a major global health issue, characterized by high incidence and mortality rates. This study aims to further elucidate the function of H domain of Fc fragment of IgG binding protein (HFCGBP), asa candidate tumor suppressor gene, in the progression of CRC and its clinical implications. Methods A comprehensive methodological approach was employed, encompassing the collection of clinical samples, proliferation and migration assays, immunohistochemistry, and in-depth data analysis. Results The downregulation of FCGBP expression was significant negatively correlated with tumor stage and grade in CRC tissues. Importantly, the overexpression of HFCGBP in CRC cells resulted in a notable inhibition of cell proliferation and migration, highlighting its potential as a therapeutic target. Combined with bioinformatic analysis of RNA-seq, the key signaling pathways modulated by HFCGBP, such as neuroactive ligand-receptor interaction and platelet activation, were identified, thereby offering valuable insights into its regulatory mechanisms. Furthermore, the analysis of TCGA and Gene Expression Omnibus (GEO) databases further confirmed the reduced expression of FCGBP in various tumor types, with a particular focus on CRC, reinforcing its potential as a prognostic biomarker. It underscores the crucial role of HFCGBP in CRC and its promising potential as a therapeutic target. Keywords FCGBP, H domain, Colorectal cancer, Therapeutic target, Prognostic biomarker, RNA-sequence †Qiao Liu and Hong-ying Jiao have been equally contributed to the work. *Correspondence: Wei Zhang [zhwlyh@fmmu.edu.cn](zhwlyh@fmmu.edu.cn)[ ](zhwlyh@fmmu.edu.cn)Na Ning [ningnnwin@163.com](ningnnwin@163.com)[ ](ningnnwin@163.com)Li Gong [glzwd16@fmmu.edu.cn](glzwd16@fmmu.edu.cn) 1Department of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China 2Department of Oncology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China 3Department of Clinical Laboratory, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China 4College of Animal Science and Technology, Northwest A&F University, Yangling, China © The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.) Liu et al. BMC Cancer (2026) 26:450 Background Cancer is a major global health challenge. In recent years, although the methods of early diagnosis and treatment have e

FAQs

What is the main focus of the study in colorectal cancer?

The study focuses on the tumor-suppressive function of the unique H domain of FCGBP (HFCGBP) and its potential as a therapeutic target in colorectal cancer.

How were the effects of HFCGBP on cancer cell behavior evaluated?

The research employed clinical sample collection and functional experiments, including proliferation and migration assays, along with immunohistochemistry and in-depth data analysis.

What key results support HFCGBP as a therapeutic candidate?

FCGBP downregulation correlates negatively with tumor stage and grade, while overexpression of HFCGBP in colorectal cancer cells inhibits proliferation and migration, indicating therapeutic potential.

How does the study connect HFCGBP to prognosis and underlying mechanisms?

It integrates bioinformatic RNA-seq pathway analysis and database validation using TCGA and GEO to confirm reduced FCGBP expression and to identify signaling pathways modulated by HFCGBP, supporting prognostic biomarker value.

Sep 22, 2026

Upload by Aria Callaghan